Avacincaptad pegol clinical trials
Also written IZERVAY and ARC1905.
How each study uses avacincaptad pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 4 Aug 2023 · IZERVAY · NDA 217225 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Ophthotech Corporation (5) · Astellas Pharma Global Development, Inc. (2) · IVERIC bio, Inc. (2) · Astellas Pharma Inc (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
RO7669330 (1) · Pegcetacoplan (1) · Aflibercept (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test avacincaptad pegol.
- Jun 2027A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationPhase 4 · Astellas Pharma Inc
Studies
Open first, then newest update. How each study uses avacincaptad pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)TerminatedPhase 1Hoffmann-La RocheNCT06961370Written as Izervay™
- A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationActive, not recruitingPhase 4Astellas Pharma IncNCT06970665Written as avacincaptad pegol
- Avacincaptad Pegol Open-Label Extension for Patients With Geographic AtrophyCompletedPhase 3Astellas Pharma Global Development, Inc.NCT05536297Written as avacincaptad pegol
- Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)CompletedPhase 2Astellas Pharma Global Development, Inc.NCT03364153Written as avacincaptad pegol
- A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)CompletedPhase 3IVERIC bio, Inc.NCT04435366Written as Avacincaptad Pegol
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationCompletedPhase 2/3IVERIC bio, Inc.NCT02686658Written as Avacincaptad Pegol
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)CompletedPhase 2Ophthotech CorporationNCT03362190Written as Avacincaptad Pegol
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)CompletedPhase 2Ophthotech CorporationNCT02397954Written as Avacincaptad Pegol
- ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular DegenerationCompletedPhase 1Ophthotech CorporationNCT00709527Written as Avacincaptad Pegol
- A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationCompletedPhase 1Ophthotech CorporationNCT00950638Written as Avacincaptad Pegol
- ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)WithdrawnPhase 2Ophthotech CorporationNCT03374670Written as Zimura
Given beside what is tested · 1 — avacincaptad pegol is usual care or a partner of the new treatment
Codes
What other systems call avacincaptad pegol · ClinicalTrials.gg INT002125
- MeSH (NLM) C000731678avacincaptad pegolOne source NLM
- UNII (FDA) TT0V5JLG5BAVACINCAPTAD PEGOLConfirmed FDA, NLM, Wikidata
- Wikidata Q121945069avacincaptad pegolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171668Avacincaptad PegolOne source FDA
- DrugBank DB15165One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731678 | avacincaptad pegol | One source NLM |
| UNII (FDA) | TT0V5JLG5B | AVACINCAPTAD PEGOL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q121945069 | avacincaptad pegol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171668 | Avacincaptad Pegol | One source FDA |
| DrugBank | DB15165 | — | One source Wikidata |
Also registered as avacincaptad pegol sodium (UNII K86ENL12I5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.